Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity
Journal for ImmunoTherapy of Cancer · 2024-12 · 12 (12) · e009741
DOI: 10.1136/jitc-2024-009741 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 09.12.2024. Verfasst von Daisuke Morita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Adenoviridae, Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, Naito Foundation.
Abstract (Originalsprache)
Background
Oncolytic adenoviruses (OAds) are the most clinically tested viral vectors for solid tumors. However, most clinically tested “Armed” OAds show limited antitumor effects in patients with various solid tumors even with increased dosages and multiple injections. We developed a binary oncolytic/helper-dependent adenovirus system (CAdVEC), in which tumors are coinfected with an OAd and a non-replicating helper-dependent Ad (HDAd). We recently demonstrated that a single low-dose CAdVEC expressing interleukin-12, programmed death-ligand 1 blocker, and HSV thymidine kinase safety switch (CAdTrio) induces significant antitumor effects in patients, including complete response. Similar to previous OAd studies, all patients primarily amplified Ad-specific T cells after treatment however, CAdVEC was still able to induce clinical responses even given at a 100-fold lower dose.
Methods
To address the mechanisms of CAdTrio-mediated antitumor effect in patients, we analyzed patients’ samples using Enzyme-linked immunosorbent spot (ELISpot) to measure T-cell specificity and quantitative polymerase chain reaction (qPCR) to measure CAdVEC viral genome copies at tumor sites. We then evaluated potential mechanisms of CAdVEC efficacy in vitro using live-cell imaging. Based on those results, we developed a new CAdVEC additionally expressing a T-cell engager molecule targeting CD44v6 to redirect tumor-infiltrating irrelevant T cells against cancer stem cell populations (CAdTetra) for further improvement of local CAdVEC treatment. We tested its efficacy against different cancer types both in vitro and in vivo including Ad pre-immunized humanized mice.
Results
We found that HDAd-infected cells escape Ad-specific T-cell recognition with enhanced tumor-specific T-cell activity through immunomodulatory transgenes. Since CAdVEC treatment initially amplified Ad-specific T cells in patients, we re-direct these virus-specific T cells to target tumor cells by additionally expressing CD44v6.BiTE from CAdTetra. CAdTetra significantly controlled tumor growth, repolarizing local and systemic responses against cancer cells in both immunologically “hot” and “cold” tumor models and also induced immunologic memory against rechallenged tumors.
Conclusions
Our results indicate that CAdTetra effectively induces adaptive T-cell responses against cancer cells by using tumor-infiltrating irrelevant T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
- Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA.
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
- Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Matsumoto, Japan.
- Department of Biology, School of Science and Engineering, Benedict College, Columbia, SC, USA.
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
ORCID-Profile: Caroline Porter, Mae Woods, Masataka Suzuki
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- Naito Foundation
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- Adopt-A-Scientist Funding
- International Medical Research Foundation
Zitieren
APA
Morita, D., Rosewell Shaw, A., Biegert, G., Porter, C., Woods, M., Vasileiou, S., Lim, B., & Suzuki, M. (2024). Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. Journal for ImmunoTherapy of Cancer, 12(12), e009741. https://doi.org/10.1136/jitc-2024-009741
Vancouver
Morita D, Rosewell Shaw A, Biegert G, Porter C, Woods M, Vasileiou S, et al. Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. Journal for ImmunoTherapy of Cancer. 2024;12(12):e009741. doi:10.1136/jitc-2024-009741
BibTeX
@article{Morita2024,
author = {Morita, Daisuke and Rosewell Shaw, Amanda and Biegert, Greyson and Porter, Caroline and Woods, Mae and Vasileiou, Spyridoula and Lim, Bora and Suzuki, Masataka},
title = {Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {12},
pages = {e009741},
doi = {10.1136/jitc-2024-009741}
}
EUVIMED